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Aim: Determining perturbed biochemical functions associated with tobacco 
smoking should be helpful for establishing causal relationships between exposure 
and adverse events. Results: A multiplatform comparison of serum of smokers 
(n = 55) and never-smokers (n = 57) using nuclear magnetic resonance spectroscopy, 
UPLC–MS and statistical modeling revealed clustering of the classes, distinguished 
by metabolic biomarkers. The identified metabolites were subjected to metabolic 
pathway enrichment, modeling adverse biological events using available databases. 
Perturbation of metabolites involved in chronic obstructive pulmonary disease, 
cardiovascular diseases and cancer were identified and discussed. Conclusion: 
Combining multiplatform metabolic phenotyping with knowledge-based mapping 
gives mechanistic insights into disease development, which can be applied to 
next-generation tobacco and nicotine products for comparative risk assessment.
First draft submitted: 25 May 2015; Accepted for publication: 3 August 2016; 
Published online: 16 September 2016
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One of the undisputed approaches to deter-
mine the potential health risk and diseases 
associated with lifestyle, and exposure to tox-
icological substances is epidemiology. In the 
early 1950s and 1960s, epidemiological evi-
dence linked for the first time tobacco smok-
ing with lung cancer and subsequently with 
other respiratory diseases and cardiovascular 
diseases [1–3]. Next-generation tobacco and 
nicotine products, such as electronic ciga-
rettes and heated tobacco devices, are emerg-
ing across markets with differing levels of 
regulation having limited scientific evidence 
regarding their relative risk for health [4,5]. 
Since epidemiology is retrospective in nature 
and requires a marketed product and a study 
population in which the adverse biological 
outcome may take years or decades to develop 
it cannot at this point be used to guide regu-
latory decisions on new tobacco and nico-
tine products. Furthermore, epidemiology 
does not give mechanistic information about 
the events leading to a disease. Therefore, 
biomarkers that are predictive of biologi-
cal adverse effects can inform the decisions 
and actions of policy makers and product 
developers. A toxic stress or disease will trig-
ger a tissue response, such as the secretion of 
inflammatory mediators, and can cause cell 
damage with leakage of cell material in the 
blood stream that can be detected by targeted 
assays. Such protein, miRNA and metabolite 
markers found in serum and urine have been 
used to assess tobacco product toxicity [6,7]. 
Targeted toxicological end points in bioflu-
ids, including single or multiplexed mark-
ers of inflammation and genotoxicity, give 
a useful, yet narrow and truncated view of 
the overall perturbations caused by a toxic 
stress. Thus, adverse biological events that 
might be of importance when comparing the 
risk of novel tobacco products against con-
ventional tobacco and nicotine replacement 
therapies could be missed. However, the dra-
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matic advance in detection methods, statistical mod-
els and computer sciences offers new perspective to 
apply global screens (omics) to assess adverse biological 
responses for product risk assessment. Such a multidis-
ciplinary approach applied to product risk assessment 
is often referred as systems toxicology [8,9].
In systems toxicology, a biological entity can be 
simplified to a network of genes, proteins, lipids and 
metabolites, in cells and organs interacting with each 
other in equilibrium to perform diverse functions [10]. 
A disease or a toxicological stress can be viewed as 
temporary or permanent perturbation of this net-
work homeostasis evolving over a certain period of 
time [10,11]. Theoretical pathways and disease networks 
can be built by leveraging the information present in 
medical and biological databases and queried using the 
calculating power of modern computers [12,13]. Thus if 
a detailed signature of biological perturbations caused 
by an exposure event can be obtained and mapped to 
biological pathways it potentially becomes possible to 
model the causal relationship between exposure and 
adverse events potentially leading to diseases [13]. In 
the context of risk assessment, there is an interest in 
creating a comprehensive map of the perturbed bio-
logical functions caused by tobacco smoking to use as a 
benchmark to contrast and compare conventional and 
next-generation tobacco and nicotine products both 
in vitro and in clinical samples.
Metabolic phenotyping (also known as metabo-
nomics or metabolomics) is an approach that allows 
the collection of a comprehensive signature of the met-
abolic profile of human subjects, which can be altered 
by factors, such as lifestyle, diet, medical intervention 
or diseases, for example [14]. This paradigm is particu-
larly well suited for tobacco risk assessment in clinical 
studies since it can be applied to biofluid samples not 
requiring invasive biopsy procedures that are not ethi-
cal in healthy subjects. Only a handful of studies have 
conducted a metabolic analysis of either urine, saliva 
or serum of smokers using a single- or a two-platform 
approach, such as GC–MS, capillary electrophoresis 
mass spectrometry or UPLC–MS [15–19]. Each plat-
form provides complementary coverage of the meta-
bolic space, and is built to preferentially target polar, 
lipophilic or charged metabolites; therefore a single 
platform can only acquire a fraction of a metabolic 
profile.
The objective of this study was to perform the first 
multiplatform study using a range of both combined 
NMR and MS assays to establish key metabolic pertur-
bations when the serum of smokers and nonsmokers is 
compared. Thus, within each of the two main platforms 
we used two types of NMR spectra, and four types 
of UPLC–MS, namely reverse phase (RP) and hydro-
philic (HILIC) UPLC–MS in both positive and nega-
tive ESI to determine the serum metabolome/lipidome 
of smokers and nonsmokers. Identification of bio-
logical adverse events was performed by mapping the 
metabolic perturbations to functional pathways using 
biological network knowledge-based applications. The 
impact on sphingolipids, glycerophospholipid metabo-
lism, levels of HDL and antioxidants, such as glutathi-
one, is reported and discussed in light of the current 
literature. This work highlights the potential benefit 
of applying a multiplatform metabolic phenotyping 
approach combined with knowledge-based tools for 
future evaluation of next-generation tobacco products.
Experimental section
Samples
Sixty-seven smokers and 61 never-smokers from the 
Hamburg (Germany) area were enrolled in the study 
for a period of 183 and 164 days, respectively [20]. 
Inclusion criteria were a minimum weight of 52 kg 
for men and 45 kg for women and a BMI within the 
defined healthy range with no clinical history of heart, 
lung diseases and chronic diseases. Pregnant women 
were excluded from the study. Additional require-
ments for smokers were to be a regular consumer of 
10–30 6–8 mg ISO Tar yield cigarettes/day, to be aged 
between 28 and 55 years old, to have been a smoker for 
at least 5 years and with a urinary cotinine (a major 
nicotine metabolite) level above 100 ng/ml at the point 
of screening [20]. The smokers were provided with a 
standard 7-mg ISO tar yield, 0.6-mg nicotine king-size 
commercial product (Lucky Strike Silver) to smoke for 
the duration of the study [20]. The never-smoker group 
was defined as never having smoked more than 100 
cigarettes during his/her lifetime, with no cigarettes in 
the past 5 years, no regular exposure to second-hand 
smoke and to be aged between 28 and 55 years old. 
The urinary cotinine level measured at screening and 
during the course of the study had to remain below 
30 ng/ml in never-smokers. Further details on the 
inclusion and exclusion criteria (e.g., medicines, medi-
cal conditions) are given in the published protocol by 
Shepperd et al. [20,21]. For the duration of the study, 
participants were given an electronic diary to record 
cigarette consumption, diet, exercise, medications 
and any health-related event. The diary entries were 
checked during regular ambulatory visits for proto-
col violations (days 31, 62, 95, 124 and for smokers 
at day 165). Breaches of protocol were assessed for 
severity in order to evaluate continued participation 
to the study. In-clinic evaluations with biofluid col-
lection (saliva, blood, urine) were performed on days 
14, 45, 76, 108 and 183 for smokers and on days 3, 
80 and 164 for never-smokers [20]. A period of 48 h of 
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clinical confinement with controlled diet preceded the 
biofluid sample collection with exclusion of caffeine, 
alcohol, grilled, fried and smoked food. Adherence 
to these dietary restrictions was also required 48 h 
before the visit to the clinic. A variety of biomarkers 
of tobacco smoke exposure and biological effects listed 
in Shepperd et al. [20] were measured in blood, serum, 
saliva and urine and the data were published in Shep-
perd et al., Haswell et al. and Banerjee et al. [21–23]. For 
this study, we only used serum samples collected at 
day 183 (n = 55; 28 males, 27 females) for smokers 
and day 164 (n = 57; 29 males, 28 females) for never-
smokers who completed the study. The total nicotine 
equivalent quantification (TNEQ) was performed 
in urine as previously described [21]. Table 1 presents 
the summary demographic information on the par-
ticipants who completed the study and the detailed 
anonymized metadata including recent past medi-
cal history are accessible on the MetaboLights data-
base [24] (accession number: MTBLS364). The study 
protocol and informed consent forms were approved 
by the Ethics Committee of the Ärztekammer Ham-
burg, Germany and the clinical study was conducted 
in accordance with the World Medical Association 
Declaration of Helsinki (World Medical Association, 
2004) and ICH Guidelines for Good Clinical Practice 
(ICH, 1996). The study was registered in the Cur-
rent Controlled Trials database under the reference 
ISRCTN81286286. Cessation counseling was pro-
vided during the course and at the end of the study 
through workshops, and lectures assisted by a trained 
psychologist to develop individual plans for quit-
ting. Voluntary-free enrollment was provided for the 
Smoke-Free counselling Programme of the Institut für 
Gesundheitsförderung, which also comprises a relapse 
prevention phase [20].
Chemicals
LC–MS grade solvents were used throughout the 
application. Acetonitrile, isopropanol, formic acid, 
ammonium formate, sodium phosphate, trimeth-
ylsilyl-[2,2,3,3,-2H
4
]-propionate, deionized water 
and deuterated water were all purchased from Sigma 
Aldrich, UK.
Sample preparation
Frozen serum samples (-80°C) were thawed and then 
centrifuged at 2700 × g for 10 min to remove par-
ticulates and precipitated proteins. Serum samples 
were prepared for metabolic profiling analysis by RP 
and HILIC UPLC–MS as follows: 200 μl of super-
natant was treated (1:3) with isopropanol, incubated 
at -20°C for 24 h, centrifuged at 2700 × g for 20 min 
and aliquoted for HILIC and RP methods. QC sam-
ples were prepared by pooling 50 μl volumes of each 
sample. During the analysis, the samples were main-
tained at 4°C in the autosampler and separated and 
analyzed using both RP and HILIC chromatographic 
methods [25]. Alternatively, 300 μl of individual serum 
samples were prepared with pH 7.4 phosphate buffer, 
as described previously for high-resolution 1H-NMR 
spectroscopy [26].
Instrumentation
RP and HILIC UPLC–MS metabolic profiling experi-
ments were performed using a Waters Acquity Ultra 
Performance LC system (Waters, MA, USA) coupled 
to a Xevo G2 Q-TOF mass spectrometer (Waters, MA, 
USA) with an electrospray source. 1H-NMR metabolic 
profiling analysis of blood serum was performed at 
300K on a Bruker Avance spectrometer at 600 MHz 
(Bruker Biospin, Rheinstetten, Germany).
Table 1. Summary demographic for subjects who completed the clinical study and provided samples 
used in this metabolic phenotyping study.
  Smokers, n = 55 Never-smokers, n = 57
Age (years) Mean ± SD 39.7 ± 8.8 42.4 ± 7.2 
 Median (min, max) 43 (24, 54) 44 (28, 55)
Gender (n) Females 27 28
 Males 28 29
BMI (kg/m2) Mean ± SD 24.7 ± 2.5 25.0 ± 2.7
 Median (min, max) 24.4 (18.6, 30) 25.0 (18.8, 30)
Ethnicity Caucasians 55 55
 NonCaucasians 0 2
Exposure TNEQ (μg/ml) Mean ± SD 8.4 ± 4.9 BLOQ
Cigarettes per day Mean ± SD (over study duration) 21.6 ± 7.5 0
BLOQ: Below limit of quantification; SD: Standard deviation of the mean; TNEQ: Total nicotine equivalent.
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Reverse phase & HILIC UPLC–MS conditions
The serum samples were first subjected to analy-
sis using UPLC–MS, with an RP chromatographic 
method with both positive and negative MS ioniza-
tion detection. Second, to separate and detect more 
polar molecules, an HILIC chromatographic stage 
was used with both positive and negative MS ioniza-
tion detection. Separation of lipid components by the 
RP method was performed according to the Waters 
application publication [27].
HILIC separation was performed as previously 
described [25] and samples were analyzed in a random 
order. Capillary and cone voltages were set at 1.5 kV 
and 30 V, respectively. The desolvation gas was set to 
1000 l/h at a temperature of 600°C; the cone gas was 
set to 50 l/h and the source temperature was set to 
120°C. For mass accuracy a lock–spray interface was 
used with leucine–enkephalin (556.27741/554.2615 
amu) solution at a concentration of 2000 ng/ml and at 
a flow rate of 15 μl/min as the lock mass.
1H-NMR conditions
The serum samples were analyzed using 1H-NMR 
spectroscopy with two different pulse sequences [26]. 
The first, the so-called noesy–presat sequence pro-
vides an overview of all proton-containing species and 
yields sharp peaks for small molecule species, broad 
bands from the lipoproteins (used later for lipopro-
file analysis, see below) and a broad largely featureless 
background from proteins, the most abundant being 
albumin. The second-pulse sequence, the so-called 
Carr-Purcell-Meiboom-Gill (CPMG) sequence, takes 
advantage of the different nuclear spin relaxation 
times between large and small molecules to attenu-
ate the peaks from large molecules (those with shorter 
spin–spin relaxation times) to leave mainly small 
molecule metabolite peaks. The main data analysis 
was performed using the CPMG spectral data and 
the lipoprotein profiling was carried out using the 
noesy–presat spectral data. For the CPMG spectra 
a relaxation delay of 4 s, a mixing time of 0.01 s, a 
spin–echo delay of 0.3 ms, 128 loops and a free induc-
tion decay acquisition time of 3.067 s were used. A 
total of 32 scans were recorded into 96 k data points 
with a spectral width of 20 ppm.
Data treatment
All the raw spectra for the different platform have 
been uploaded and are accessible on the MetaboLights 
database [24] (accession number: MTBLS364). The 
raw mass spectrometric data acquired were processed 
using xcms in R [28] and the centwave peak picking 
methods were used to detect chromatographic peaks. 
The xcms-centwave parameters were dataset specific. 
Data were normalized using probabilistic quotient 
normalization [29] using the median spectrum as the 
reference.
The acquired 1H-NMR spectra were zero-filled to 
128 k points, Fourier transformed, phase and baseline 
corrected using Bruker Topspin 3.1 (Bruker Biospin, 
Rheinstetten, Germany). The serum spectra were ref-
erenced to the anomeric proton assigned to α-glucose 
at δ5.22 and imported to MATLAB™ (R2014a, The 
Mathworks, MA, USA) for further analysis. Regions 
corresponding to the water peak (δ4.3–4.925) were 
removed. All spectra were normalized using proba-
bilistic quotient normalization [28] using the mean 
s pectrum as the reference.
Lipoprotein profiles from deconvolution of 
NMR peak shapes
Quantification of lipoprotein subclasses was obtained 
from deconvolution of the methyl peak near δ0.89 using 
a Bruker (Bruker Biospin, Rheinstetten, Germany) 
procedure based on the method of Petersen et al. [30]. 
For QC purposes, the Bland–Altman prediction 
errors and correlations coefficients were calculated 
using the conventional values and the Bruker NMR 
measurement of total HDL, LDL, triglycerides and 
cholesterol. The measurement quality is in line with 
and meets the Bruker routine standard, therefore the 
complete analysis of 105 lipoprotein subclasses was 
performed including different chemical components of 
IDL (density 1.006–1.019 kg/l), VLDL (0.950–1.006 
kg/l), LDL (density 1.09–1.63 kg/l) and HDL (density 
1.063–1.210 kg/l). The LDL subfraction was separated 
in six density classes (LDL-1 1.019–1.031 kg/l, LDL-2 
1.031–1.034 kg/l, LDL-3 1.034–1.037 kg/l, LDL-4 
1.037–1.040 kg/l, LDL-5 1.040–1.044 kg/l, LDL-6 
1.044–1.063 kg/l) and the HDL subfraction in four 
density classes (HDL-1 1.063–1.100 kg/l, HDL-2 
1.100–1.125 kg/l, HDL-3 1.125–1.175 kg/l, HDL-4 
1.175–1.210 kg/l). Based on their lipoprotein frac-
tionation protocol, Bruker has implemented a specific 
nomenclature for the 105 lipoprotein components (see 
Supplementary Table 1).
Statistical analysis
Multivariate statistical analysis was used to examine 
the datasets and to observe clustering in the results 
according to predefined classes. The dominant source 
of variations in each data matrix and the outliers were 
identified by PCA.
Univariate logistic regression was performed, adjust-
ing for confounding factors between never-smokers 
and smokers with class variables (BMI, gender, admin-
istered medications and age) for each NMR and MS 
feature in the datasets. Linear regression of the meta-
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bolic data was performed against urinary TNEQ as 
the dependent variable. For each NMR variable/MS 
feature, a regression coefficient was obtained from 
the logistic regression model, and was converted to a 
t-score and subsequently to a p-value. These p-values 
were adjusted for multiple testing using the Ben-
jamini–Hochberg false discovery rate (pFDR) method. 
All variables/features that have a pFDR ≤ 5% are con-
sidered to be significantly associated with the separa-
tion of the never-smokers or smokers groups and are 
subsequently represented in a Manhattan plot.
Metabolite identifications
Metabolite identification of significant MS features 
employed online database searches (METLIN) [31], 
human metabolome database (HMDB) [32] and Lipid 
MAPS® [33]. Confirmation of such metabolite identi-
fications was obtained using further MS–MS experi-
ments and comparison to MS fragmentation patterns 
in the literature.
Confirmation of metabolite identities in the NMR 
data was obtained using 1D and 2D NMR experiments, 
spike-in of chemical standards, JRES (J-Resolved 
spectroscopy), (TOCSY) TOtal Correlation Spectros-
copY and HSQC (Hetero-nuclear 1H-[13]C Single 
Quantum Coherence) spectroscopy.
The identification of a metabolite was character-
ized by a level of assignment (LoA) score that describes 
how the identification was made (adapted from Sum-
ner et al. [34]). The LoA used for the molecules identified 
by MS are LoA 1: identified compound, confirmed by 
comparison to an authentic chemical reference, LoA 2: 
MS/MS spectrum matched to database or literature to 
putatively annotate compound, LoA 3: accurate mass 
(m/z) matched to database and detection of common 
fragment ion to putatively characterize the compound 
classes, LoA 4: accurate mass (m/z) matched to data-
base to make a tentative assignment. The LoA of the 
1H-NMR peaks are reported as follows: LoA 1: iden-
tified compound, confirmed by adding the authentic 
chemical compound to the plasma samples (spike-in 
experiments) LoA 2: 1H-NMR chemical shifts and 
their multiplicity matched to database or literature to 
putatively annotate the compound.
Pathway enrichment analysis
HMDB [32] and Lipid MAPS® [33] were searched to 
obtain an overview of the classes of metabolites that 
were most affected by smoking using the tentatively 
identified metabolites in our dataset. Functional 
enrichment analysis of statistically significant metabo-
lites was performed using MetaboAnalyst 3.0 [35,36] to 
interpret some of the observed metabolic changes. A 
cutoff value of pFDR ≤ 0.05 was used for Metabo-
Analyst unfiltered for fold change, and filtered to 
only include metabolites with a fold change of 10% 
or more.
Results
Metabolic phenotype data
Smokers’ and never-smokers’ metabolic phenotype 
data were obtained by analyzing the serum samples 
with three different analytical platforms. The acquired 
data were organized into six separate datasets, namely 
CPMG NMR spectra, lipoprotein fraction data, RP 
UPLC–MS data (positive and negative ionization 
separately) and HILIC UPLC–MS data (positive and 
negative ionization separately) that were used for fur-
ther statistical analysis. The lipoprotein fraction data 
were based on deconvolution of the complex lineshape 
of the methyl peak arising from lipoproteins in the 
noesy–presat NMR spectra,
The noesy–presat and CPMG 1H-NMR spectra and 
representative RP and HILIC UPLC–MS profiles of 
smokers are shown in Figure 1A–F. Table 2 summarizes 
the number of features detected with each analytical 
platform.
Statistical analysis of the metabolic phenotype 
data
To discover any natural clustering by class end point 
(smoking status as the target end point, and gender 
as a potential confounder end point) in the metabolic 
data, PCA analysis was applied to all six datasets 
1H NMR, NMR-lipoprotein fraction data, HILIC 
UPLC–MS (ESI+), HILIC UPLC–MS (ESI-), RP 
UPLC–MS (ESI+) and RP UPLC–MS (ESI-)). The 
information from this analysis is displayed for illustra-
tive purposes only as score plots in which each colored 
spot represents one individual. The PCA score plots 
of PC1 versus PC2 for the six datasets are shown in 
Supplementary Figure 1. When the data points are 
color-coded for smoking status, examination of all 
of the PCs for all six datasets show some degree of 
clustering with the MS-derived data giving greater 
clustering when assessed visually. From the PCA 
score plots of the MS data in particular it was shown 
that smoking status is the major source of data vari-
ance contributing to the first PCs and for the HILIC 
UPLC MS data there is separation in PC1. As a typi-
cal possible confounder variable, the gender effect 
was also investigated using the PCA data. When the 
points are color-coded by gender it can be seen for all 
six datasets there is a degree of clustering by gender 
with the variation due to this end point contribut-
ing to PC2. In this study HILIC UPLC–MS showed 
the best smoker/nonsmoker s eparation in PCA 
(Supplementary Figure 1).
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Figure 1. Metabolic phenotyping data of serum samples from smokers (see facing page). Median 1H NMR 
(A) Noesy–presat and (B) CPMG spectra. Base peak intensity (BPI) chromatograms from (C) positive ESI mode 
(ESI+), (D) negative ESI mode (ESI-) from the RP-UPLC–MS analysis; (E) ESI+ and (F) ESI- from the HILIC UPLC–MS 
analysis. L1: Lipids methyl group: CH3-(CH2)n or CH3-CH2-CH2C=, L2: Lipids : methylene group: CH3-CH2-CH2, (CH2)n 
or CH3-CH2(CH2)n, L3: Lipids: methylene group: CH2-CH2-CH2-CO, L4: Lipids: methylene group: CH2-CH2-CO or CH2-
C=C, L5: Lipids: methylene group: CH2-C=O, α–AA: Alpha amino acids. 
CE: Cholesterol ester; DG: Diacylglycerol; PC: Phosphatidylcholine; PE: Phophatidylethanolamine; 
PG: Phosphatidylglycerol; SM: Sphingomyelin; TG: Triacylglycerol.
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Univariate logistical regression and multiple factor 
correction analysis Figure 2A–C was applied to all six 
metabolic datasets to compare the metabolic profiles of 
never-smokers and smokers, taking into account varia-
tion caused by the variables that would potentially con-
found the data, such as gender variation that was already 
observed in the PCA.
As a result of applying this multiplatform approach, 
significantly different metabolites between the two classes 
were obtained after accounting for any variation caused 
by differences in age, gender and drug intake. The total 
number of discriminating features is shown in Table 2 
with their corresponding analytical platform. The tenta-
tively identified metabolites significant at pFDR ≤ 0.05 
with at least one identifier in HMDB [32], Pubchem [37], 
CHEbi [38], KEGG [39] or Lipid MAPS® [33] are listed in 
Table 3. The fold changes in these metabolites between 
smokers and never-smokers, the pFDR values, analytical 
platform and mass are also summarized in Table 3.
Among the identified metabolites, glutathione 
and citrate decrease in the CPMG NMR serum pro-
files (Figure 2A & Table 3) of smokers while glutamate 
increases in the serum of smokers.
Similar results are evident for the four UPLC–MS 
datasets as seen in Figure 2B based on the retention 
times and observed m/z values for metabolites that dif-
ferentiate smokers and never-smokers at pFDR ≤ 0.05. 
The identified candidates are listed in Table 3. Those 
tentatively identified lipids that were detected using 
more than one ionization mode or platform include 
LysoPC(18:0), LysoPC(16:0), SM(18:1/20:4) and 
SM(d18:1/23:0) (Table 3).
Using normalized intensity values box plot examples 
of six tentatively identified metabolites that are signifi-
cantly different between smokers and nonsmokers are 
presented in Figure 3. These six metabolites are further 
examined in the discussion due to their potential link 
with cardiovascular diseases or emphysema.
The univariate logistic regression approach was also 
used to analyze the results from the lipoprotein frac-
tion analysis from the NMR data. The main compo-
nents (cholesterol, free cholesterol, phospholipids and 
triglycerides) of LDL subclasses 5 and 6 were found 
to be increased in serum of smokers compared with 
the never-smokers, see Figure 2C. These LDL subfrac-
tions constitute the most HDL from the analyzed 
Table 2. Summary of platforms and features.
Method Detected Significant S 
v NS
Filtering hits for acceptance 
criteria† 
Included in 
pathway 
enrichment‡,§ 
1H-NMR CPMG 187,998 data 
points
767 data points 767 data points. Among 
these, three metabolites were 
identified
3 metabolites
Lipoprotein 
fraction data
105 lipoprotein 
components
12 12 0
RP UPLC–MS (ESI+) 739 MS features 230 MS features 175 MS features (84 metabolites 
of which 31 remain unassigned)
49 metabolites
RP UPLC–MS (ESI-) 529 MS features 115 features 82 MS features (30 metabolites 
of which 16 remain unassigned)
2 metabolites
HILIC UPLS–MS 
(ESI+)
732 MS features 336 features 146 MS features (44 metabolites 
of which 8 remain unassigned)
20 metabolites
HILIC UPLC–MS 
(ESI-)
220 MS features 101 MS features 28 MS features (18 metabolites) 8 metabolites
† All significant hits (features) discovered using UPLC–MS are manually extracted from the raw data to assign the nature of the ion (parent, 
isotope or adduct). At this stage it is also possible to identify features that are false positives and in the noise. These are removed from the 
list.
‡ Metabolites with an HMDB, PubChem, CHEbi, KEGG or lipidmaps ID.
§ Some metabolites were detected with multiple platforms and are highlighted in Table 3.
CPMG: Carr-Purcell-Meiboom-Gill; HILIC: Hydrophilic; NS: Never-smokers; RP: Reverse phase; S: Smokers.
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LDL pool. (LDL-5 10.10–1.044 kg/l and LDL-6: 
1.044–1.063 kg/l). In addition, Apolipoprotein-B in 
total serum and the overall LDL subfraction were both 
found higher in smokers compared with never-smokers.
Linear regression analysis against the TNEQ 
measure & BMI
Linear regression was also carried out using the results 
from all six sets of the metabolic phenotyping data 
against a measure of the TNEQ present in the urine [34]. 
TNEQ is an independent measure of how much nico-
tine was absorbed into the system. The smoking group 
only is considered for this analysis, since nicotine is not 
detected in never-smokers. This calculation was per-
formed uncorrected and corrected for age, gender and 
BMI. The regression of the NMR data to TNEQ was 
not significant.
In addition, from the RP UPLC–MS (ESI-) data, the 
isotope of the parent ([M+H]+) ion of PE(O-18:1/20:4) 
was detected and this was negatively associated with 
TNEQ with a false discovery p-value of pFDR = 0.00596. 
The pFDR p-value of the parent ion was not significant. 
In the HILIC UPLC–MS (ESI+) data, there was a fea-
ture positively associated with TNEQ with a false discov-
ery p-value of pFDR = 0.00287. On first inspection, this 
feature could be an isotope of the sodiated ([M+Na]+) 
ion of PE(O-18:1/20:4). The pFDR p-value of the sodi-
ated ion itself was not significant. Thus, in both of these 
datasets the assignment of PE(O-18:1/20:4) discovered 
using UPLC–MS was based solely on the detection of 
an isotope ion. This equivocal result suggests that there 
may be coelution of another molecule in either or both 
of the datasets and that this molecule may be misas-
signed. Therefore, it was not used for further functional 
pathways analyses.
Linear regression of the lipoprotein fraction and 
RP UPLC MS (ESI+) data to TNEQ was not sig-
nificant. To investigate a possible major confounder, a 
similar calculation was carried using BMI in the uni-
variate model, uncorrected and corrected for age and 
gender. The 1H-NMR data analysis showed no sig-
nificant features being correlated with BMI. The lipo-
protein analysis did reveal an increase in cholesterol 
(pFDR = 0.02905), phospholipids (pFDR = 0.02905) 
and apolipoprotein-B (pFDR = 0.02905) of the LDL 
subclass 5 (particle size: 1.040–1.044 kg/l) when 
regressed against BMI but the correlation was weak. 
Further information and statistics for these models can 
be found in Supplementary Figures 2 & 3.
Pathway enrichment analysis
A list of tentatively identified metabolites is shown in 
Table 3, and Supplementary Table 2 presents the metab-
olite ontologies based on HMDB and LIPID Maps® G
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Figure 2. Differences in the metabolic phenotyping data between smoker and never-smoker groups after 
correction for confounders (BMI, gender age and drug intake) (cont.). (A) Manhattan plot of the NMR CPMG 
data. A significant p-value threshold of 0.05 was chosen after calculating the false discovery rate (FDR) and is 
marked with the dotted line. The red spots relate to NMR data points that highly correlate with the individuals 
in the smokers group, the blue spots are the data points that highly correlate to the never-smokers group. 
(B) Manhattan plots for all four UPLC–MS datasets showing the retention time on the x-axis and the m/z value on 
the y-axis for each significant (pFDR ≤ 0.05) feature. The color of the spot relates to the direction of the correlation 
(smokers, red and never-smokers, blue) and the shading shows the strength of the correlation (the darker the 
color the more significant). (C) Histogram showing the 12 lipoprotein subclasses (mean ± standard error) being 
significantly different (pFDR < 0.05) between never-smokers (green) and smokers (red). L5PL: phospholipids in LDL 
subclass 5, L5AB, apolipoprotein in LDL subclass 5, L5CH: cholesterol in LDL subclass 5, L5FC, free cholesterol in 
LDL subclass 5, L5TG: triglycerides in LDL subclass 5, TPAB: apolpoliprotein-B in total plasma, L6TG: triglycerides in 
LDL subclass 6, L6CH: cholesterol in LDL subclass 6, L6PL: phospholipids in LDL subclass 6, L6AB: apolipoprotein-B 
in LDL subclass-6, L6FC: free cholesterol in LDL subclass 6, LDAB: apolipoprotein-B in total LDL subclass. Particle 
size of LDL subclass 5 (LDL-5): 1.040–1.044 kg/l. Particle size of LDL subclass 6 (LDL-6): 1.044–1.063 kg/l. The 
lipoproteins were fractionated according to their density size by a sedimentation method adapted from literature 
by Bruker. The lipoprotein nomenclature is specific to the Bruker lipoprotein fractionation protocol list of 105 
lipoprotein measurements in given in Supplementary Table 1. 
CPMG: Carr-Purcell-Meiboom-Gill.
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classification for the main compounds that were 
changed in smokers compared with never-smokers.
A functional enrichment analysis was conducted 
using MetaboAnalyst [35,36] and the tentatively identi-
fied metabolites at pFDR ≤ 0.05 in smokers relative 
to never-smokers with no fold-change filter criteria (50 
single metabolites with HMDB IDs). MetaboAna-
lyst allowed the plotting of the enrichment profile as 
a function of the enrichment -log
2
 (p-value) and the 
pathway impact (%) (Figure 4). Perturbations in eight 
pathways were highlighted on the MetaboAnalyst plot 
with the four most significant features contained in 
the limits of a -log
2
 (p-value) threshold of 3 (p < 0.05) 
and a minimum of 10% impact (Figure 4). The enrich-
ment for sphingolipid metabolism, glycerophospho-
lipid metabolism and the various amino acids path-
ways were well aligned with the major HMDB and 
Lipid MAPS® ontology classes found in our dataset 
(Supplementary Table 2). If a fold-change filter crite-
rion of 10% had been applied to conduct the Metabo-
Analyst enrichment, the resulting 44 metabolites 
would have returned a very similar result in terms of 
enriched categories (results not shown). Overall simi-
larly enriched categories are also obtained if only the 
metabolites tentatively identified with an LoA of 3 or 
lower are used, however, the reported pathway impact 
and significance is reduced (Supplementary Figure 4).
Discussion
Systems toxicology consists of the integrative study of 
the biological perturbations caused by toxicants using 
untargeted in vitro and in vivo screens combined with 
computational tools to determine possible toxicologi-
cal outcomes. The development of next-generation 
tobacco and nicotine products offers a significant 
opportunity to reduce the burden on population 
health caused by tobacco use, but epidemiological data 
are currently lacking. In this context, systems toxicol-
ogy could form part of a weight-of-evidence approach 
for next-generation tobacco product risk assessment. 
The first step would be to create a comprehensive map 
of tobacco smoking-related biological perturbations 
that can be interrogated for comparison against novel 
potentially reduced risk tobacco and nicotine products. 
The objective of the current study was to use a multi-
platform metabolic phenotyping approach to gain a 
detailed insight into perturbed metabolic markers in 
healthy human smokers and apply a pathway enrich-
ment analysis to identify functional changes associated 
with chronic smoking.
Both NMR and MS approaches were used in this 
study. The relative merits and sensitivities of the two 
approaches have been well documented previously and 
it is well known that the various platforms are highly 
complementary [40,41]. MS is generally more sensitive 
than NMR but the coverage of metabolic space is 
highly assay specific whereas, although NMR is less 
sensitive, a metabolite will give an NMR spectrum if it 
contains hydrogens [40]. For instance one of the NMR 
profiles gives the comprehensive information on lipo-
protein subfractions while RP UPLC–MS is optimum 
for the individual lipid species that are embedded in 
many of the different lipoproteins [42], while HILIC 
UPLC–MS targets mainly polar molecules [40]. A broad 
metabolic phenotyping approach was chosen here to 
provide an exploratory overview of as wide a cover-
age as possible and this methodology is known to be 
semi-quantitative and reproducible [25–26,43]. It is pos-
sible to employ assays targeted at specific metabolites 
that would be more quantitative but this was not done 
herein as those would bias any subsequent functional 
enrichment analysis based on the selected targets. The 
multiplatform approach we used has found widespread 
application in large cohort studies [44] as multiple ana-
lytical techniques provide detection of a broad range 
of metabolites with diverse physicochemical properties.
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Figure 3. Changes in smoking-related metabolites in current and never-smokers. Box plots of the S and NS groups are illustrated 
for (A) glutathione, (B) bilirubin, (C) L-kynurenine, (D) LysoPC(18:2), (E) LysoPC(16:0) and (F) Cer(18:1/24:1). For each group, the 
five parameters are the lowest intensity of the metabolite, lower quartile, median, upper quartile and highest intensity. The points 
outside the quartiles are outliers. 
The data used herein are normalized intensities expressed in arbitrary units (au). 
NS: Never-smokers; S: Smokers.
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Moreover, the complementarity of the various plat-
forms is illustrated by the natural variance in the data 
shown in the PCA scores plots when color-coded 
by the various desired and confounder end points 
(Supplementary Figure 1). For example, when the points 
are color-coded by gender it can be seen for all six data-
sets there is a degree of clustering by gender with the 
variation due to this end point contributing to PC2. 
In this particular study HILIC UPLC–MS showed 
the best smoker/never-smoker separation in PCA 
(Supplementary Figure 1). It cannot be concluded, how-
ever, that this platform is sufficient to conduct a detailed 
comparison of smokers and never-smokers since all of the 
technology platforms provide some degree of separation 
for both the target end point and confounder end points 
based on complementary coverage of the metabolic space.
In terms of standardization and validation, the 
approach already in the literature was followed for NMR 
spectroscopy [26] and this has been shown to be highly 
reproducible. Similarly for the MS assays, protocols devel-
oped for high-throughput large-scale studies were fol-
lowed with comprehensive use of QC samples as defined 
by Lewis et al. [43].
In this study, we used the Probabilistic Quotient 
Normalization method, which accounts for dilution 
effects of complex matrices by calculating the most 
probable dilution factors [29]. Because this normaliza-
tion approach is not influenced by the change of single-
peak intensities or by baseline distortion, it has been 
shown to perform better than two other commonly 
used metabolic phenotyping normalization methods 
in complex matrices, particularly in serum samples 
which contain large broad signals from lipids and 
proteins [29]. It is therefore ideal for subsequent data 
analysis.
In terms of validation of metabolite assignments, we 
adapted the approach proposed by Sumner et al. [34], 
which uses a ‘LoA’ confidence scale. A decreasing score 
value from 4 to 2 indicates increased confidence in 
the molecular identity of a metabolite by matching a 
combination of accurate mass, common fragment ions 
and common spectrum to repository databases. A score 
of 1 denote identification using a synthetic standard. 
Due to the size of our datasets non-novel metabolites 
were putatively identified, and those with an LoA of 
2 had the highest degree of assignment short of full 
www.future-science.com 2037
Figure 4. Functional pathway and ontologies enrichment analyses. MetaboAnalyst enrichment plot for 
metabolites significant at pFDR < 0.05. Top perturbed pathways based on impact and -log2 (p-value) are 
labeled on the graph. The -log2 (p-value) is the enrichment score. The impact score (0–1) indicated the pathway 
topological importance of the metabolites.
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identification by authentic standard. LoA assignment 
combined with fold change and statistical significance 
offers the advantage of enabling the prioritization of 
metabolites for further identification with authentic 
standards as this can be a time consuming step. All 
multivariate and univariate statistical models were 
validated using appropriate statistical measures, cor-
recting for false positive and confounding variables, as 
is conventional in the literature, as for example shown 
in Elliot et al. [44].
Metabolites of biological interest were discovered 
from each of the datasets (1H NMR, HILIC UPLC–
MS, RP UPLC–MS and Bruker NMR lipoprotein 
profiles). The tentatively identified metabolites and 
LoA are presented in Table 3. An overview of the 
underlying biological changes occurring between 
smokers and never-smokers was obtained by func-
tional enrichment analysis. Two annotation databases, 
namely HMDB, and Lipid MAPS®, were used to 
search for metabolites ontology using the list of tenta-
tively identified metabolites (Supplementary Table 2). 
The enrichment analysis was performed with the 
metabolites significant at pFDR ≤ 0.05 with or with-
out a fold-change criterion of more than 10% in 
smokers compared with never-smokers. The enriched 
functional pathways were visualized using Metabo-
Analyst [35,36] and are shown in Figure 4. From these 
different analyses multiple pathways emerged as the 
top enriched categories impacted by smoking: sphin-
golipid and glycerophospholipid metabolism, amino 
acid metabolism (D-glutamate, glycine, serine, thre-
onine, lysine, arginine) and aminoacyl t-RNA bio-
synthesis were highlighted. Those can be further cat-
egorized based on the current weight of evidence for 
their association with specific diseases. Sphingolipids 
and glycerophospholipids are modified by oxidative 
stress, which is involved in inflammation processes 
leading to cardiovascular diseases and emphy-
sema [45,46]. Furthermore, other metabolic phenotyp-
ing studies in smokers using single analytical plat-
forms or targeted approaches have also identified a 
subset of the pathways found in our analysis. The 
KORA (Cooperative Health Research in the region 
of Augsburg) study, which used a targeted metabolite 
approach screened 140 and 198 metabolites in serum, 
and identified a strong impact of smoking on glyc-
erophospholipids, sphingolipids, amino acids, such as 
arginine and glycine and aminoacyl-tRNA metabo-
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lism [19,47]. Monoacylglycerophosphocholine was one 
of the glycerophospholipid class proportionally more 
impacted (11 [14.5%] out of a total of 76 listed in 
Lipid Maps) by smoking. In this subclass of lipids 
LysoPC(16:0) is one example for which an increased 
level has been shown to be linked with carotid intima 
thickness in smokers [48]. In agreement with this 
observation LysoPC(16:0) was increased by 60% in 
our analysis (Figure 3). We also detected an increase 
of LysoPC(18:2) (Figure 3), one glycerophospholipid 
that has been demonstrated to have an association 
with the risk of coronary heart disease and mortal-
ity [45,49]. However, the reported association with 
risk of coronary heart disease was inversely related to 
the level of LysoPC(18:2) in serum and age-depen-
dent [45]. On the other hand higher levels of LysoPCs 
have also been observed as a result of LDL oxidation 
which converts them into atherogenic particles [50]. 
This illustrates the complexity of understanding the 
dynamics of individual lipid markers with regards to 
risk. Yet, in general, glycerophospholipids are thought 
to have protective qualities for the cardiovascular sys-
tem [49] and we observed a reduction of more than 
10% for a total of 19 of them (Lipid MAPS®) across 
different subfamilies. Alteration of glycerophospho-
lipids and glutamate were also reported in a UPLC-
TOF-MS metabolomics cross-sectional clinical study 
with smokers [17], which also reported an effect on 
carbohydrate metabolism.
In addition, we observed an increase of small higher 
density LDL subclasses (LDL-5, 1.040–1.044 kg/l, 
LDL-6, 1.044–1.063 kg/l) and APO-B measured 
by NMR in our smoker group (Figure 2). Increased 
levels of small higher density LDL has been linked 
to higher risk of coronary heart diseases and carotid 
intima thickness [51,52]. The small and dense LDL 
particles are more likely to be glycated or oxidized 
than normal LDL particles. They can easily access the 
subendothelial space where they trigger inflammation 
and undergo a transformation into plaque, thus pro-
moting atherosclerosis [53]. Finally, we also report a 
marked increase of L-kynurenine in our smoker group 
(Figure 3). L-kynurenine has been recently investi-
gated as a marker of cardiovascular risk in particu-
lar in obese people who had an increase serum ratio 
L-kynurenine/tryptophan and is therefore potentially 
a promising biomarker of cardiovascular risk. There 
remain however some severe challenges to the identi-
fication of a panel of lipids and metabolites in smok-
ers predictive of cardiovascular diseases, which would 
require multiple cohorts and a prospective design [54].
Our analysis also pointed toward a change in 
the abundance of sphingolipids including changes 
in the ceramide and sphingomyelin subclasses 
(Figure 4; Supplementary Table 2). More specifically, 
the ceramide Cer(d18:1/24:1[15Z]) appeared to be 
a strong responder to cigarette smoke with a 1.5-fold 
increase (Figure 3). The expression of COL4A3BP, 
a candidate gene in the etiology of COPD has been 
correlated with the level of Cer(d18:1/24:1(15Z)) in 
COPD patients [55], but to this date it is not known 
whether this sphingolipid is predictive of the onset of 
COPD in healthy smokers. Cer(d18:1/24:1(15Z)) is, 
therefore, an interesting candidate biomarker to fol-
low in a longitudinal study to establish whether this 
lipid has a predictive value in early COPD diagnosis. 
Lower levels of the sphingomyelins SM(d18:1/14:0) 
and SM(d18:2/14:01) have also been reported in the 
serum of COPD patients [55]. We also detected lower 
levels of those two sphingolipids in our screen of 
healthy smokers, albeit those reductions were modest 
(Table 3) and there is currently no evidence that those 
lipids are predictive of disease. Sphingolipids are sig-
naling molecules involved in processes, such as apopto-
sis, cell cycle and inflammation [43,44], which contrib-
ute to tobacco-specific diseases development, however, 
the balance between apoptotic and mitotic promotion 
by sphingolipids, such as ceramides and sphingomy-
elins in lung disease is not well understood. This has 
been reviewed in detail by Goldkorn et al. who sug-
gested the involvement of ceramide-dependent exo-
some excretion of miRNA that regulate EGFR, a cell 
growth regulator [56] that plays a role in both COPD 
and lung cancer. For example they mentioned let-7a 
as a candidate miRNA associated with lung cancer 
poor clinical outcome and others reported that miR-
124 was also correlated with tumor metastasis in non-
small-cell lung cancer [56,57]. Interestingly, in a screen 
of 80 miRNA that we performed in the same serum 
samples, those were the two miRNAs that we found 
altered as a function of smoking status [22,58].
A recent global metabolic phenotyping study (using 
C18-UPLC–MS/MS and GC–MS) of blood (EDTA-
plasma and serum) from 892 men and women from 
four studies identified metabolites related to cigarette 
smoking behavior in current smokers [59]. Twenty-four 
metabolites were statistically significant after Bonfer-
roni correction based on p-values of fixed-effect meta-
analyses (0.05/700 = 7.1 × 10-5). Fifteen metabolites 
were derived from xenobiotics possibly originating 
from tobacco smoking and coffee consumption. The 
endogenous metabolites implicated phenylalanine and 
tyrosine, benzoate and tryptophan metabolism [59]. 
Our study (Table 3) and the study from Gu et al. [59] 
both identified bilirubin as significantly lower in 
smokers. Bilirubin is a well-known blood antioxi-
dant that is inversely correlated with increased risk of 
coronary heart disease and lung cancer [60–62]. Glu-
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tathione was another antioxidant highlighted in our 
study to be significantly lower in the serum of smokers 
(Figure 3), which other studies have linked to a higher 
risk of cardiovascular disease [63]. The smaller number 
of metabolites identified in the large study described 
above can originate from the use of the highly strin-
gent Bonferroni false discovery rate and the combi-
nation of samples obtained from multiple studies 
with different designs and objectives. Furthermore, 
our study included methods aimed at lipid profiling, 
which in our case formed the majority of features 
differentiating smokers and never-smokers.
We also conducted linear regression analysis of the 
metabolic data to TNEQ and BMI. Linear regression 
of the metabolic and lipoprotein data in our study has 
shown no correlation with nicotine dose (TNEQ) while 
three lipoproteins (cholesterol, phospholipids and apo-
lipoprotein-B of the LDL subclass 5) were weakly cor-
related with BMI (Supplementary Figures 2 & 3). The 
lack of correlation with nicotine dose is not entirely 
surprising since TNEQ was measured in urine not in 
serum and TNEQ is only representative of the smok-
ing behavior over the 24 h prior to sampling due to 
its short half-life. Endogenous metabolic perturba-
tions are likely to accumulate over a prolonged period 
of time on a different scale compared with TNEQ. 
Therefore, correlation with TNEQ might not yield 
meaningful results regarding the dose–response rela-
tionship. A larger study group might be required to 
establish clear dose–response relationships or the use 
of a blood marker of smoke exposure, such as the 
acrylonitrile hemoglobin adduct, which is representa-
tive of cigarette consumption over a period of several 
months.
The strength of our study lies in the use of mul-
tiple platforms giving extensive coverage of the serum 
metabolome with robust statistical analysis but it also 
has limitations. The way in which the study was con-
ducted did not lead itself to trying to identify whether 
each individual could be predicted to be a smoker or a 
never-smoker. We were interested in finding metabo-
lites that statistically could distinguish the groups, 
smoker versus never-smoker. Given the modest sam-
ple numbers and the large number of features we took 
care to validate the multivariate models carefully and 
robustly. This precluded the generation of training 
and tests sets that could be used for class prediction or 
individual status prediction. The multivariate mod-
els were used to show class trends but the significant 
metabolites were identified by using univariate mod-
eling but with comprehensive removal of variance 
caused by confounding variables. Of course, if the 
subject had smoked within the previous 48 h of giving 
a sample, then the nicotine metabolites present would 
be the best way to identify an individual’s status. 
This is another reason why we did not do individual 
predictions in this study.
Our enrichment analysis using MetaboAnalyst is a 
qualitative assessment and therefore it does not pre-
dict whether a pathway is up or down regulated, but 
is more representative of the topological perturbations 
of a pathway. Tools, such as IPA Ingenuity®, offer the 
possibility to perform downstream causal prediction 
based on reference pathways [64] and inclusive of fold 
change, however the knowledge-base of Ingenuity 
currently includes very limited data on lipids. The rel-
evance of pathways identified in our enrichment anal-
ysis, such as aminoacyl-tRNA biosynthesis, should be 
considered carefully. Indeed, there is a clear overlap 
between the metabolites found in those and pathways 
relating to amino acids metabolism, and furthermore 
the number of signature metabolites mapping to some 
pathways can be low. Other key factors to consider in 
interpreting the data are the fold change of the ten-
tatively identified metabolites, and the level of con-
fidence in the metabolite identification (LoA rank). 
We opted for a pFDR < 0.05 and a 10% fold change 
filter to conduct part of our enrichment analysis and 
we cannot exclude that a number of included metabo-
lites might be false positives. Filters are arbitrary in 
nature and it is not uncommon to find metabolic phe-
notyping studies where, for example, only a statistical 
significance filter is used [65,66]. A higher fold-change 
filter and lower pFDR value might yield greater con-
fidence in the metabolites used to predict perturbed 
pathways and functions with a trade-off of potentially 
eliminating others that might turn out to be biologi-
cally relevant. Finally, in this study no confirmation 
of metabolite identification using synthetic standard 
materials was performed and therefore it is possible 
that some metabolites especially with a high LoA 
might be reclassified. Therefore, this study primar-
ily illustrates a multiplatform strategy from samples 
acquisition, analysis, selection of features of interests 
with an example of pathway enrichment applica-
tion. The identification stage is in itself a significant 
piece of work and as shown in Table 2, many features 
remain unassigned. Addressing this would increase 
the robustness and granularity of any subsequent 
enrichment analysis. As more and more detailed spec-
tra populate public repositories it is expected that the 
confidence in the identification of metabolic features 
will be increasingly facilitated.
Finally, our study was performed with a relatively 
small number of subjects with an overrepresentation 
of the Caucasian ethnic background and no clinical 
confinement, our results are in close agreement with 
the KORA study, which was conducted on a large 
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group of Korean smokers [19]. This indicates that 
those metabolic alterations are present independently 
of the ethnic group. Furthermore, in light of our 
results and the KORA study a full clinical confine-
ment to control for confounding factors, such as diet, 
does not appear to be required to detect smoking-
specific events in serum. However, as a minimum, a 
diary of taken medications should be kept for possible 
confounder corrections.
Conclusion
Applying a multiplatform, metabolic-phenotyping 
approach produced a rich dataset that in combina-
tion with a knowledge-based enrichment analysis 
gave mechanistic insights into biological alterations 
potentially associated with tobacco-related diseases 
in healthy smokers. The dataset and enrichment 
analysis are in agreement with previously published 
single platform metabolomics, lipidomics and bio-
markers studies pointing toward an impact of smok-
ing on antioxidants, such as glutathione, bilurubin 
and lipids involved in apoptosis and cardiovascular 
diseases. Our study together with the few other 
related studies in smokers contributes to strengthen 
the weight of evidence of functional alterations 
caused by smoking. The reversibility of these altera-
tions in metabolic pathways should be investigated 
for their use as risk assessment benchmarks in stud-
ies where smokers are switched to next-generation 
tobacco and nicotine products, such as electronic 
cigarettes. Further validation of the candidate 
metabolites could be performed by evaluating 
whether a panel of identified metabolites can pre-
dict the smoking status of test subjects and which 
ones are predictive of disease onset in prospective 
clinical s tudies.
Future perspective
The development of next-generation tobacco and nico-
tine products offers a significant opportunity to reduce 
the burden of tobacco use on population health, but 
epidemiological data are currently lacking. In this con-
text, systems toxicology could form part of a weight of 
evidence approach for tobacco product risk assessment. 
The use of metabolic phenotyping tools in clinical 
studies of smokers who switched to those novel devices 
or quit smoking altogether should provide further 
insights into the reversibility of those pathway pertur-
bations and potential benefits of switching. Applica-
tion of these approaches to in vitro cell systems, such 
as reconstituted airway epithelium exposed to aero-
sols, could further complement the risk assessment of 
next-generation tobacco and nicotine devices.
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